Genentech’s Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
Genentech, a unit of Roche Holdings AG (OTC:RHHBY), announced that the Phase 3 IMbrave050 study met its primary endpoint of recurrence-free survival…